BCL2L1 and Thrombocytopenia: LOXO-338 (Eli Lilly, Indianapolis, IN, USA) is a novel inhibitor of BCL-2, designed to inhibit Bcl-2 over Bcl-xL selectively and to avoid dose-limiting thrombocytopenia associated with Bcl-xL inhibition [94].